{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:59:53Z","timestamp":1788199193293,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Giant cell arteritis (GCA) is a large vessel vasculitis that primarily involves aorta and its major branches. Cerebral infarction is a serious complication that can occur secondary to GCA in up to 3% of patients with a mortality rate of over 50%. Due to the rarity of this severe complication, no therapeutic strategies are currently available. Furthermore, despite the recent progress in molecular-targeted therapy for GCA, it remains unknown whether tocilizumab is effective for severe ischemic complications such as cerebral infarction. The accumulation of individual cases in which this fatal complication could be treated is apparently required to build a better management of the disease. We present our case of GCA that developed severe cerebral infarction during high-dose glucocorticoid and tocilizumab therapy, and its symptoms and image findings were improved by switching to intravenous cyclophosphamide. Our case suggests that an intensive immunosuppressive therapy, including cyclophosphamide, may be necessary to stabilise this fatal complication of GCA.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad009","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T10:50:24Z","timestamp":1675075824000},"page":"453-457","source":"Crossref","is-referenced-by-count":4,"title":["A severe cerebral infarction associated with giant cell arteritis, which developed during tocilizumab therapy and was successfully treated with intravenous cyclophosphamide"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ishigaki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"2023061920014378500_R1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023061920014378500_R2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMcp1214825","article-title":"Clinical practice. Giant-cell arteritis and polymyalgia rheumatica","volume":"371","author":"Weyand","year":"2014","journal-title":"N Engl J Med"},{"key":"2023061920014378500_R3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2019.02.007","article-title":"Cytokines, growth factors and proteases in medium and large vessel vasculitis","volume":"206","author":"Weyand","year":"2019","journal-title":"Clin Immunol"},{"key":"2023061920014378500_R4","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2023061920014378500_R5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3899\/jrheum.161033","article-title":"Giant cell arteritis\u2013related stroke: a retrospective multicenter case-control study","volume":"44","author":"de Boysson","year":"2017","journal-title":"J Rheumatol"},{"key":"2023061920014378500_R6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.150143","article-title":"Severe intracranial involvement in giant cell arteritis: 5 cases and literature review","volume":"43","author":"Alsolaimani","year":"2016","journal-title":"J Rheumatol"},{"key":"2023061920014378500_R7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/art.22359","article-title":"Giant cell arteritis: involvement of intracranial arteries","volume":"55","author":"Salvarani","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023061920014378500_R8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2023061920014378500_R9","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2013-204167","article-title":"Performance of the new 2012 EULAR\/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study","volume":"73","author":"Macchioni","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023061920014378500_R10","article-title":"Innate and adaptive immunity in giant cell arteritis","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front Immunol"},{"key":"2023061920014378500_R11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2023061920014378500_R12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/rheumatology\/kez511","article-title":"Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study","volume":"59","author":"Saito","year":"2020","journal-title":"Rheumatology"},{"key":"2023061920014378500_R13","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-022-05217-x","article-title":"Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy","author":"Higashida-Konishi","year":"2022","journal-title":"Rheumatol Int"},{"key":"2023061920014378500_R14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ana.26101","article-title":"Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype","volume":"90","author":"Beuker","year":"2021","journal-title":"Ann Neurol"},{"key":"2023061920014378500_R15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5114\/reum.2021.105414","article-title":"Giant cell arteritis presenting as a stroke in the internal carotid artery territory: a case-based review","volume":"59","author":"Conticini","year":"2021","journal-title":"Reumatologia"},{"key":"2023061920014378500_R16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/NRL.0000000000000237","article-title":"Recurrent stroke in giant cell arteritis despite immunotherapy","volume":"24","author":"Cox","year":"2019","journal-title":"Neurologist"},{"key":"2023061920014378500_R17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.1972.00490170010003","article-title":"Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement","volume":"27","author":"Wilkinson","year":"1972","journal-title":"Arch Neurol"},{"key":"2023061920014378500_R18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000504018","article-title":"Isolated bilateral internal carotid artery stenosis and recurrent ischemic strokes in a patient with suspected giant cell arteritis","volume":"12","author":"Oerding","year":"2020","journal-title":"Case Rep Neurol"},{"key":"2023061920014378500_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000265","article-title":"Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study","volume":"93","author":"Larivi\u00e8re","year":"2014","journal-title":"Medicine"},{"key":"2023061920014378500_R20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/acr2.11161","article-title":"Clinical and radiographic features of giant cell arteritis with intracranial involvement","volume":"2","author":"Sanchez-Alvarez","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2023061920014378500_R21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","article-title":"Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine"},{"key":"2023061920014378500_R22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","article-title":"Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis","volume":"88","author":"Gonzalez-Gay","year":"2009","journal-title":"Medicine"},{"key":"2023061920014378500_R23","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-019-04339-y","article-title":"Risk of ischaemic events at giant cell arteritis diagnosis according to PET\/CT findings","volume":"46","author":"Mestre-Torres","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023061920014378500_R24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","article-title":"Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis","volume":"48","author":"Salvarani","year":"2009","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad009\/49435747\/rxad009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/453\/50646555\/rxad009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/453\/50646555\/rxad009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T20:07:57Z","timestamp":1687205277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/2\/453\/7008760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,28]]},"published-print":{"date-parts":[[2023,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad009","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,1,28]]}}}